Dimensional Fund Advisors’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$304M Sell
512,739
-15,471
-3% -$7.7M 0.06% 346
2025
Q4
$257M Buy
528,210
+15,394
+3% +$7.17M 0.05% 421
2025
Q3
$215M Sell
512,816
-60,918
-11% -$20.5M 0.05% 496
2025
Q2
$165M Sell
573,734
-50,977
-8% -$15.2M 0.04% 638
2025
Q1
$193M Buy
624,711
+4,145
+0.7% +$1.42M 0.05% 497
2024
Q4
$219M Sell
620,566
-466
-0.1% -$171K 0.05% 436
2024
Q3
$223M Buy
621,032
+35,063
+6% +$11.8M 0.05% 428
2024
Q2
$187M Buy
585,969
+22,683
+4% +$6M 0.05% 484
2024
Q1
$129M Buy
563,286
+1,336
+0.2% +$301K 0.04% 754
2023
Q4
$124M Buy
561,950
+9,962
+2% +$2.3M 0.04% 727
2023
Q3
$125M Buy
551,988
+17,234
+3% +$3.97M 0.04% 634
2023
Q2
$118M Buy
534,754
+17,077
+3% +$3.78M 0.04% 692
2023
Q1
$116M Buy
517,677
+22,169
+4% +$5.47M 0.04% 680
2022
Q4
$138K Sell
495,508
-33,014
-6% -$8.33M 0.04% 540
2022
Q3
$111M Buy
528,522
+4,174
+0.8% +$933K 0.04% 616
2022
Q2
$124M Sell
524,348
-37,618
-7% -$7.65M 0.04% 566
2022
Q1
$101M Sell
561,966
-12,270
-2% -$2.34M 0.03% 844
2021
Q4
$124M Sell
574,236
-26,423
-4% -$5.19M 0.04% 707
2021
Q3
$111M Sell
600,659
-56,936
-9% -$11.2M 0.04% 750
2021
Q2
$118M Sell
657,595
-96,388
-13% -$18.4M 0.04% 706
2021
Q1
$126M Sell
753,983
-132,351
-15% -$22.1M 0.04% 626
2020
Q4
$135M Sell
886,334
-16,421
-2% -$2.15M 0.05% 515
2020
Q3
$91.2M Buy
902,755
+110,152
+14% +$12.1M 0.04% 650
2020
Q2
$95.9M Sell
792,603
-106,404
-12% -$12M 0.04% 591
2020
Q1
$85.3M Buy
899,007
+14,674
+2% +$1.39M 0.04% 537
2019
Q4
$77.9M Buy
884,333
+34,137
+4% +$3M 0.03% 973
2019
Q3
$67.8M Buy
850,196
+580
+0.1% +$46.7K 0.03% 1064
2019
Q2
$66.3M Sell
849,616
-225,227
-21% -$21.1M 0.03% 1108
2019
Q1
$126M Sell
1,074,843
-14,139
-1% -$1.65M 0.05% 478
2018
Q4
$119M Buy
1,088,982
+29,427
+3% +$3.41M 0.05% 409
2018
Q3
$135M Buy
1,059,555
+68,870
+7% +$8.52M 0.05% 468
2018
Q2
$112M Buy
990,685
+32,611
+3% +$3.58M 0.04% 565
2018
Q1
$108M Buy
958,074
+10,129
+1% +$1.29M 0.04% 569
2017
Q4
$140M Buy
947,945
+149,852
+19% +$19M 0.06% 401
2017
Q3
$93.5M Buy
798,093
+71,333
+10% +$9.11M 0.04% 636
2017
Q2
$94.3M Buy
726,760
+266,790
+58% +$33.3M 0.04% 579
2017
Q1
$62.3M Buy
459,970
+8,759
+2% +$1.33M 0.03% 923
2016
Q4
$64.7M Buy
451,211
+153,165
+51% +$19.6M 0.03% 839
2016
Q3
$35.2M Buy
298,046
+86,970
+41% +$10.4M 0.02% 1423
2016
Q2
$22.4M Buy
211,076
+9,258
+5% +$1.03M 0.01% 1741
2016
Q1
$22.5M Buy
201,818
+63,525
+46% +$8.04M 0.01% 1718
2015
Q4
$21.7M Buy
138,293
+4,251
+3% +$619K 0.01% 1719
2015
Q3
$17.6M Sell
134,042
-54,047
-29% -$8.67M 0.01% 1876
2015
Q2
$32.7M Buy
188,089
+4,236
+2% +$762K 0.02% 1339
2015
Q1
$31.7M Buy
183,853
+1,341
+0.7% +$204K 0.02% 1324
2014
Q4
$23.6M Sell
182,512
-1,565
-0.9% -$202K 0.02% 1571
2014
Q3
$23.7M Buy
184,077
+13,549
+8% +$1.4M 0.02% 1442
2014
Q2
$15.1M Sell
170,528
-581
-0.3% -$55.9K 0.01% 1911
2014
Q1
$16.1M Buy
171,109
+2,421
+1% +$248K 0.01% 1788
2013
Q4
$19.1M Buy
168,688
+4,284
+3% +$386K 0.01% 1606
2013
Q3
$13M Buy
164,404
+8,299
+5% +$607K 0.01% 1870
2013
Q2
$10.3M Buy
+156,105
New +$10.1M 0.01% 1970

Other funds holding UTHR

Dimensional Fund Advisors's UTHR Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its United Therapeutics (UTHR) stake by 2.9% in Q1 2026, selling an estimated $7.7M and leaving 512,739 shares worth $304M. The position accounts for 0.06% of the portfolio, ranked #346.

Dimensional Fund Advisors first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Dimensional Fund Advisors held 512,739 shares of United Therapeutics worth $304M as of Q1 2026.
  • Dimensional Fund Advisors sold 15,471 United Therapeutics shares in Q1 2026, an estimated $7.7M.
  • United Therapeutics made up 0.06% of Dimensional Fund Advisors's portfolio in Q1 2026, its #346 holding.
  • Dimensional Fund Advisors first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.